Jonathan A. Ledermann
Impact in
- Reproductive Medicine top 0.01%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.05%
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Ovarian cancer diagnosis and treatment 170
- Oncology 158
- PARP inhibition in cancer therapy 105
- Colorectal Cancer Treatments and Studies 21
- Lung Cancer Research Studies 10
- Cancer Immunotherapy and Biomarkers 7
- Co-authors
- Gordon C. Jayson (17 shared papers)Elise C. Kohn (3 shared papers)Nicoletta Colombo (41 shared papers)Henry Charles Kitchener (5 shared papers)Gordon J.S. Rustin (29 shared papers)Michael Leonard Friedlander (25 shared papers)Antonio González-Martı́n (19 shared papers)Philipp Harter (17 shared papers)
- Journals
- Annals of Oncology (65 papers)International Journal of Gynecological Cancer (62 papers)Gynecologic Oncology (37 papers)British Journal of Cancer (27 papers)The Lancet Oncology (20 papers)
- Partner nations
- United KingdomUnited StatesItaly
In The Last Decade
Jonathan A. Ledermann
385 papers receiving 36.8k citations
Jonathan A. Ledermann's Hit Papers
Peers
Comparison fields: 5 of 146
- Reproductive Medicine 12.2k
- Oncology 12.6k
- Obstetrics and Gynecology 5k
- Cancer Research 1.6k
- Genetics 2.4k
Countries citing papers authored by Jonathan A. Ledermann
This map shows the geographic impact of Jonathan A. Ledermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan A. Ledermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan A. Ledermann more than expected).
Fields of papers citing papers by Jonathan A. Ledermann
This network shows the impact of papers produced by Jonathan A. Ledermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan A. Ledermann. The network helps show where Jonathan A. Ledermann may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan A. Ledermann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 402 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Hit paper breakdown → | 2016 | 2026 |
| 2 | A Phase 3 Trial of Bevacizumab in Ovarian Cancer Hit paper breakdown → | 2011 | 1747 |
| 3 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1574 |
| 4 | Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer Hit paper breakdown → | 2012 | 1554 |
| 5 | Ovarian cancer Hit paper breakdown → | 2014 | 1542 |
| 6 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1405 |
| 7 | ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma Hit paper breakdown → | 2020 | 1388 |
| 8 | Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Hit paper breakdown → | 2014 | 1215 |
| 9 | ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up Hit paper breakdown → | 2015 | 1081 |
| 10 | Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Hit paper breakdown → | 2003 | 975 |
| 11 | ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease Hit paper breakdown → | 2019 | 900 |
| 12 | Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2013 | 888 |
| 13 | Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial Hit paper breakdown → | 2015 | 703 |
| 14 | Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study Hit paper breakdown → | 2019 | 647 |
| 15 | ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer Hit paper breakdown → | 2015 | 617 |
| 16 | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial Hit paper breakdown → | 2013 | 543 |
| 17 | Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial Hit paper breakdown → | 2017 | 502 |
| 18 | 2007 | 468 | |
| 19 | Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial Hit paper breakdown → | 2018 | 466 |
| 20 | Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2022 | 414 |
About Jonathan A. Ledermann
Jonathan A. Ledermann is a scholar working on Reproductive Medicine, Oncology, Obstetrics and Gynecology, Radiology, Nuclear Medicine and Imaging and Hepatology, having authored 402 papers that have together received 37.8k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (170 papers), PARP inhibition in cancer therapy (105 papers), Endometrial and Cervical Cancer Treatments (31 papers), Colorectal Cancer Treatments and Studies (21 papers), Radiopharmaceutical Chemistry and Applications (13 papers), Lung Cancer Research Studies (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Ethics in Clinical Research (6 papers). The work is most often cited by research in Reproductive Medicine (12.2k citations), Oncology (12.6k citations), Obstetrics and Gynecology (5k citations), Cancer Research (1.6k citations) and Genetics (2.4k citations). Jonathan A. Ledermann has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Gordon C. Jayson, Elise C. Kohn, Nicoletta Colombo, Henry Charles Kitchener, Gordon J.S. Rustin, Michael Leonard Friedlander, Antonio González-Martı́n, Philipp Harter, Fharat A. Raja and Charlie Gourley. Their work appears in journals such as Annals of Oncology, International Journal of Gynecological Cancer, Gynecologic Oncology, British Journal of Cancer and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.